Faisal Khurshid
Stock Analyst at Leerink Partners
(0)
# 4783
Out of 5,270 analysts
16
Total ratings
27.27%
Success rate
-22.51%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Pliant Therapeutics | Downgrades: Market Perform | 33 2 | 1.4 | 42.86% | 2 | Mar 3, 2025 | |
aTyr Pharma | Initiates Coverage On: Outperform | 16 | 3.29 | 386.32% | 1 | Feb 18, 2025 | |
Kymera Therapeutics | Maintains: Outperform | 60 60 | 30.14 | 99.07% | 2 | Dec 27, 2024 | |
ANI Pharmaceuticals | Initiates Coverage On: Outperform | 80 | 58.23 | 37.39% | 1 | Dec 11, 2024 | |
Zura Bio | Initiates Coverage On: Outperform | 15 | 1.18 | 1171.19% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 7 | 4.26 | 64.32% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 45 | 18.3 | 145.9% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 5 | 1.53 | 226.8% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 24 | 25.93 | -7.44% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 7 | 1.72 | 306.98% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 8 | 5.12 | 56.25% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 5 | 1.17 | 327.35% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 17 21 | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 11 | 2.18 | 404.59% | 1 | Mar 21, 2023 |